May 14, 2020 / 1:28 PM / 22 days ago

BRIEF-Pulmatrix Reports Qtrly Loss Per Share $0.23

May 14 (Reuters) - Pulmatrix Inc:

* Q1 REVENUE $2.8 MILLION

* PULMATRIX - CURRENTLY PLAN TO INITIATE PUR1800 PH1B CLINICAL STUDY AND CHRONIC TOXICOLOGY STUDIES IN SECOND HALF OF 2020

* PULMATRIX - ENROLLMENT IN PHASE 2B CLINICAL STUDY OF PULMAZOLE FOR TREATMENT OF ABPA HAS BEEN TEMPORARILY PAUSED

* PULMATRIX - QTRLY LOSS PER SHARE $0.23 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below